Clinical trial
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic…
NCT00477191 · Massachusetts General Hospital, Other · Terminated
Key facts
| NCT number | NCT00477191 |
|---|---|
| Title | Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis |
| Official title | Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Amgen Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 18 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | May 22, 2007 |
| Last update posted | May 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: